vs

Side-by-side financial comparison of Bloomin' Brands, Inc. (BLMN) and GLOBUS MEDICAL INC (GMED). Click either name above to swap in a different company.

Bloomin' Brands, Inc. is the larger business by last-quarter revenue ($975.2M vs $826.4M, roughly 1.2× GLOBUS MEDICAL INC). GLOBUS MEDICAL INC runs the higher net margin — 17.0% vs -1.4%, a 18.4% gap on every dollar of revenue. On growth, GLOBUS MEDICAL INC posted the faster year-over-year revenue change (25.7% vs 0.3%). GLOBUS MEDICAL INC produced more free cash flow last quarter ($202.4M vs $63.7M). Over the past eight quarters, GLOBUS MEDICAL INC's revenue compounded faster (16.7% CAGR vs -4.5%).

Bloomin' Brands, Inc. is a restaurant holding company that owns several American casual dining restaurant chains. The company was established in 1988 in Tampa, Florida, where it is headquartered.

Globus Medical, Inc. is a publicly traded orthopedic medical device company headquartered in Audubon, Pennsylvania, United States. Globus is focused on the design, development, and commercialization of products that enable surgeons to promote healing in patients with musculoskeletal disorders.

BLMN vs GMED — Head-to-Head

Bigger by revenue
BLMN
BLMN
1.2× larger
BLMN
$975.2M
$826.4M
GMED
Growing faster (revenue YoY)
GMED
GMED
+25.4% gap
GMED
25.7%
0.3%
BLMN
Higher net margin
GMED
GMED
18.4% more per $
GMED
17.0%
-1.4%
BLMN
More free cash flow
GMED
GMED
$138.7M more FCF
GMED
$202.4M
$63.7M
BLMN
Faster 2-yr revenue CAGR
GMED
GMED
Annualised
GMED
16.7%
-4.5%
BLMN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BLMN
BLMN
GMED
GMED
Revenue
$975.2M
$826.4M
Net Profit
$-13.5M
$140.6M
Gross Margin
70.2%
68.4%
Operating Margin
-1.4%
20.5%
Net Margin
-1.4%
17.0%
Revenue YoY
0.3%
25.7%
Net Profit YoY
83.0%
430.4%
EPS (diluted)
$-0.16
$1.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLMN
BLMN
GMED
GMED
Q4 25
$975.2M
$826.4M
Q3 25
$928.8M
$769.0M
Q2 25
$1.0B
$745.3M
Q1 25
$1.0B
$598.1M
Q4 24
$972.0M
$657.3M
Q3 24
$910.0M
$625.7M
Q2 24
$999.4M
$629.7M
Q1 24
$1.1B
$606.7M
Net Profit
BLMN
BLMN
GMED
GMED
Q4 25
$-13.5M
$140.6M
Q3 25
$-45.9M
$119.0M
Q2 25
$25.4M
$202.8M
Q1 25
$42.2M
$75.5M
Q4 24
$-79.5M
$26.5M
Q3 24
$6.9M
$51.8M
Q2 24
$28.4M
$31.8M
Q1 24
$-83.9M
$-7.1M
Gross Margin
BLMN
BLMN
GMED
GMED
Q4 25
70.2%
68.4%
Q3 25
70.4%
67.2%
Q2 25
70.2%
66.6%
Q1 25
70.1%
67.3%
Q4 24
71.6%
59.9%
Q3 24
71.3%
56.8%
Q2 24
70.5%
58.7%
Q1 24
70.5%
60.2%
Operating Margin
BLMN
BLMN
GMED
GMED
Q4 25
-1.4%
20.5%
Q3 25
-3.9%
17.9%
Q2 25
3.0%
10.2%
Q1 25
5.5%
16.2%
Q4 24
1.7%
9.2%
Q3 24
0.9%
7.7%
Q2 24
4.4%
7.9%
Q1 24
6.6%
1.3%
Net Margin
BLMN
BLMN
GMED
GMED
Q4 25
-1.4%
17.0%
Q3 25
-4.9%
15.5%
Q2 25
2.5%
27.2%
Q1 25
4.0%
12.6%
Q4 24
-8.2%
4.0%
Q3 24
0.8%
8.3%
Q2 24
2.8%
5.0%
Q1 24
-7.8%
-1.2%
EPS (diluted)
BLMN
BLMN
GMED
GMED
Q4 25
$-0.16
$1.01
Q3 25
$-0.54
$0.88
Q2 25
$0.30
$1.49
Q1 25
$0.50
$0.54
Q4 24
$-0.93
$0.19
Q3 24
$0.08
$0.38
Q2 24
$0.32
$0.23
Q1 24
$-0.96
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLMN
BLMN
GMED
GMED
Cash + ST InvestmentsLiquidity on hand
$59.5M
$557.2M
Total DebtLower is stronger
$787.4M
Stockholders' EquityBook value
$333.6M
$4.6B
Total Assets
$3.2B
$5.3B
Debt / EquityLower = less leverage
2.36×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLMN
BLMN
GMED
GMED
Q4 25
$59.5M
$557.2M
Q3 25
$66.5M
$18.8M
Q2 25
$50.3M
Q1 25
$57.7M
Q4 24
$70.1M
$890.1M
Q3 24
$83.6M
$71.9M
Q2 24
$117.9M
$82.5M
Q1 24
$131.7M
$80.4M
Total Debt
BLMN
BLMN
GMED
GMED
Q4 25
$787.4M
Q3 25
$962.2M
Q2 25
$917.1M
Q1 25
$917.6M
Q4 24
$1.0B
Q3 24
$1.1B
Q2 24
$1.0B
Q1 24
$951.8M
Stockholders' Equity
BLMN
BLMN
GMED
GMED
Q4 25
$333.6M
$4.6B
Q3 25
$344.1M
$4.4B
Q2 25
$397.2M
$4.3B
Q1 25
$380.6M
$4.1B
Q4 24
$135.5M
$4.2B
Q3 24
$242.1M
$4.1B
Q2 24
$286.8M
$4.0B
Q1 24
$302.7M
$3.9B
Total Assets
BLMN
BLMN
GMED
GMED
Q4 25
$3.2B
$5.3B
Q3 25
$3.3B
$5.1B
Q2 25
$3.3B
$5.0B
Q1 25
$3.3B
$4.7B
Q4 24
$3.4B
$5.3B
Q3 24
$3.4B
$5.1B
Q2 24
$3.4B
$5.0B
Q1 24
$3.4B
$4.9B
Debt / Equity
BLMN
BLMN
GMED
GMED
Q4 25
2.36×
Q3 25
2.80×
Q2 25
2.31×
Q1 25
2.41×
Q4 24
7.58×
Q3 24
4.51×
Q2 24
3.49×
Q1 24
3.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLMN
BLMN
GMED
GMED
Operating Cash FlowLast quarter
$119.1M
$248.6M
Free Cash FlowOCF − Capex
$63.7M
$202.4M
FCF MarginFCF / Revenue
6.5%
24.5%
Capex IntensityCapex / Revenue
5.7%
5.6%
Cash ConversionOCF / Net Profit
1.77×
TTM Free Cash FlowTrailing 4 quarters
$96.8M
$588.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLMN
BLMN
GMED
GMED
Q4 25
$119.1M
$248.6M
Q3 25
$34.4M
$249.7M
Q2 25
$49.7M
$77.9M
Q1 25
$73.5M
$177.3M
Q4 24
$119.8M
$210.3M
Q3 24
$-7.8M
$203.7M
Q2 24
$42.4M
$54.3M
Q1 24
$73.8M
$52.4M
Free Cash Flow
BLMN
BLMN
GMED
GMED
Q4 25
$63.7M
$202.4M
Q3 25
$-5.7M
$213.9M
Q2 25
$11.1M
$31.3M
Q1 25
$27.7M
$141.2M
Q4 24
$66.7M
$193.2M
Q3 24
$-67.3M
$161.7M
Q2 24
$-12.1M
$26.5M
Q1 24
$20.0M
$23.8M
FCF Margin
BLMN
BLMN
GMED
GMED
Q4 25
6.5%
24.5%
Q3 25
-0.6%
27.8%
Q2 25
1.1%
4.2%
Q1 25
2.6%
23.6%
Q4 24
6.9%
29.4%
Q3 24
-7.4%
25.8%
Q2 24
-1.2%
4.2%
Q1 24
1.9%
3.9%
Capex Intensity
BLMN
BLMN
GMED
GMED
Q4 25
5.7%
5.6%
Q3 25
4.3%
4.7%
Q2 25
3.8%
6.2%
Q1 25
4.4%
6.0%
Q4 24
5.5%
2.6%
Q3 24
6.5%
6.7%
Q2 24
5.5%
4.4%
Q1 24
5.0%
4.7%
Cash Conversion
BLMN
BLMN
GMED
GMED
Q4 25
1.77×
Q3 25
2.10×
Q2 25
1.95×
0.38×
Q1 25
1.74×
2.35×
Q4 24
7.94×
Q3 24
-1.13×
3.93×
Q2 24
1.49×
1.71×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BLMN
BLMN

Food And Beverage$958.0M98%
Franchiseand Other Revenue$17.2M2%
International Franchise Segment$7.8M1%

GMED
GMED

Other$391.8M47%
Nevro Merger Agreement$293.6M36%
Enabling Technologies$141.0M17%

Related Comparisons